D4Dent Logo

Mouth Ulcer Not Healing? When to See a Dentist

For patients

On this page

Introduction

Recurrent aphthous stomatitis, the familiar recurring "canker sore", is described in one review as a common chronic disease of the oral mucosa that affects about 20% of the population [PMID 35395126]. The most common form heals within about two weeks [PMID 8665304]. Some ulcers, however, do not heal, and an ulcer that persists is one of the recognised presentations of oral cancer [PMID 18795514].

This distinction matters in India. In the most recent regional estimates (GLOBOCAN 2022), the age-standardised incidence rate of lip and oral cancer in men was highest in India among the countries of South and South-East Asia, at 14.67 per 100,000, and the age-standardised mortality rate in men was also highest in India, at 8.17 per 100,000 [PMID 40364456].

This article summarises the evidence on the causes of mouth ulcers, how long an ordinary ulcer should take to heal, which signs need prompt examination, and what research shows about delay and screening in India. It does not replace an examination by a dentist. For a shorter overview, see our patient page on mouth ulcers.

1. Common causes of mouth ulcers

Ulcerated lesions of the mouth have many underlying causes, most commonly infection, immune-related conditions, trauma, or neoplasia (new growths, including cancer). A review of these lesions emphasises that the history should include whether a trigger can be identified, how long the lesion has been present, how often episodes recur, whether it is painful, and whether it has grown over time [PMID 30701449].

Aphthous ulcers. Recurrent aphthous stomatitis is the most common ulcerative disease of the oral mucosa, and it occurs mostly in healthy individuals [PMID 24655523]. A classic review describes three forms [PMID 8665304]:

  • Minor aphthous ulcers, the most common presentation: recurrent, round, clearly defined, small, painful ulcers that heal in 10 to 14 days without scarring.
  • Major aphthous ulcers: larger than 5 mm, they can last for 6 weeks or longer and frequently scar.
  • Herpetiform ulcers: multiple small clusters of pinpoint lesions that can coalesce into large irregular ulcers and last 7 to 10 days.

The cause is still unknown, and treatment aims to reduce pain and ulcer size, promote healing and decrease recurrence [PMID 24655523]. First-line options described in a recent review are topical medications, with systemic drugs reserved for more severe cases [PMID 35395126]; these are prescription decisions for a dentist or doctor.

Traumatic ulcers. Ulcers may be caused by mechanical, thermal or chemical irritation, such as a sharp tooth edge, a broken filling, a denture or an orthodontic wire. According to a 2025 review, in most cases traumatic ulcerations heal within two weeks once the causative irritant is removed. The same authors caution that persistent irritation can mimic oral potentially malignant disorders, and they report two patients whose lesions were initially attributed to chronic mechanical trauma but proved on biopsy to be high-grade dysplasia (carcinoma in situ) and oral squamous cell carcinoma [PMID 41431448].

In our reading, an ulcer next to a sharp tooth or denture is very likely to be traumatic, but if it has not healed about two weeks after the cause is corrected, the "obvious" explanation should not be accepted without further examination.

Infective ulcers. Infection is one of the most common underlying causes of oral ulceration [PMID 30701449]. In children, primary herpes simplex infection usually presents as herpetic gingivostomatitis, is most prevalent at 1 to 3 years of age, and lasts approximately 2 weeks [PMID 11577924]. A systematic review describes it as often self-limiting, but notes that it can limit the ability to eat and drink, sometimes requiring hospital admission [PMID 37733027]. Less commonly, the cause is bacterial; an Indian review advises dentists to include oral tuberculosis in the differential diagnosis of suspicious oral lesions [PMID 31143712].

2. The 2-to-3-week rule for a non-healing ulcer

Because ordinary ulcers follow a predictable course, duration is one of the most useful clues. The evidence points to two overlapping thresholds.

Two weeks: the expected healing time. Minor aphthous ulcers heal in 10 to 14 days [PMID 8665304], traumatic ulcers usually heal within two weeks once the irritant is removed [PMID 41431448], and primary herpetic gingivostomatitis lasts approximately 2 weeks [PMID 11577924]. An ulcer still present beyond this point has therefore outlasted the usual course of the most common benign causes. This is also the threshold used on our mouth ulcers page.

Three weeks: the point at which malignancy must be excluded. Expert reviews of oral cancer diagnosis state that the signs and symptoms of oral cancer often resemble less serious conditions, usually presenting as a lump, red or white patch or ulcer, and that if any such lesion does not heal within 3 weeks, a malignancy or some other serious disorder must be excluded and a biopsy may be indicated [PMID 18795514][PMID 16117353]. In a Canadian study of community dental practices, dentists reassessed selected lesions after 3 weeks; reassessment eliminated the referral of 99 of 166 lesions (60%) that had resolved, and the authors judged a 3-week reassessment appointment invaluable to prevent unnecessary referral [PMID 24460662].

Guideline-level evidence. An evidence-based clinical practice guideline from the American Dental Association states that for patients seeking care for suspicious lesions, immediate performance of a biopsy or referral to a specialist remains the single most important recommendation for clinical practice. The panel also emphasised the need for counselling, because patients may delay diagnosis because of anxiety and denial [PMID 28958308].

In our reading, the evidence supports a simple sequence for patients: an ulcer that has not healed within two weeks (or within two weeks of removing an obvious cause) should be seen by a dentist, and an ulcer that persists to three weeks should be investigated, which may include a biopsy. An ulcer with any of the warning signs below should be examined without waiting for either threshold.

3. Warning signs that need prompt examination

A review of ulcerated oral lesions notes that cancers in the mouth are notorious for their ability to mimic benign ulcers, and stresses that a biopsy is essential when a lesion is not clinically identifiable or does not respond as expected to treatment [PMID 30701449]. In our reading of the sources cited in this article, the features that should prompt an early visit include:

  • An ulcer that has not healed within two to three weeks [PMID 8665304][PMID 18795514].
  • An ulcer that does not respond as expected to treatment, or that grows over time [PMID 30701449].
  • An ulcer accompanied by a lump, or a red or white patch [PMID 18795514].
  • An ulcer that persists after a sharp tooth, filling or denture has been corrected [PMID 41431448].
  • Tobacco, areca nut or alcohol use, which define the high-risk groups in the screening evidence discussed below [PMID 23265945].
  • In recurrent or multiple ulcers, ulcers on the skin, genitals or eyes, or systemic symptoms such as fever or arthritis, which may indicate an underlying systemic disease [PMID 30701449].

In our reading, a painless ulcer should not be ignored simply because it does not hurt; the review cited above treats pain as one item of the history, not as a reassurance [PMID 30701449].

4. Oral potentially malignant disorders

Some changes in the lining of the mouth carry an increased risk of developing into cancer. These are called oral potentially malignant disorders (OPMDs). An international consensus convened by the WHO Collaborating Centre for Oral Cancer lists them as including leukoplakia, erythroplakia, proliferative verrucous leukoplakia, oral lichen planus, oral submucous fibrosis and palatal lesions in reverse smokers [PMID 33128420]. Our patient pages explain white or red patches and oral submucous fibrosis in more detail.

How common are they in India? A systematic review and meta-analysis of Indian population and community studies reported a point estimate from cross-sectional studies of 4.3% for leukoplakia and 2.7% for oral submucous fibrosis; in hospital-based studies, the pooled prevalence of leukoplakia was 6.7% [PMID 36159096].

How often do they become cancer? A meta-analysis of 92 studies reported an overall malignant transformation rate across all OPMD groups of 7.9%. By subtype, rates were 1.4% for lichen planus, 9.5% for leukoplakia, 5.2% for oral submucous fibrosis, 33.1% for erythroplakia and 49.5% for proliferative verrucous leukoplakia. Moderate or severe dysplasia (abnormal cells on biopsy) carried a much greater risk than mild dysplasia, with an odds ratio of 2.4 [PMID 31803979]. A 2025 meta-analysis of 55 studies including 41,231 people with leukoplakia reported a pooled malignant transformation proportion of 6.64%; the risk was higher for non-homogeneous leukoplakias, larger lesions, lesions on the lateral border of the tongue, smokers and lesions with epithelial dysplasia [PMID 39314164]. For oral submucous fibrosis, a meta-analysis of 9 observational studies with 6,337 patients reported a pooled malignant transformation proportion of 4.2%, with an annual transformation rate of 0.73%, and concluded that close to 4% of patients diagnosed with oral submucous fibrosis may develop oral cancer [PMID 33205543].

In our reading, most people with an OPMD will not develop cancer, but the risk is real and varies by type, so a persistent white or red patch, or a diagnosis of oral submucous fibrosis, should be examined and followed up by a dentist rather than watched at home.

5. Who is at higher risk: tobacco and areca nut

An analysis from the International Agency for Research on Cancer concluded that one in three cases of oral cancer globally are attributable to smokeless tobacco or areca nut consumption, and could be prevented through smokeless tobacco and areca nut control [PMID 39393386]. The proportion was 57.5% in south-central Asia [PMID 39393386]; this is a regional estimate, and the abstract does not report a figure for India alone. Our page on tobacco and oral cancer covers these risks in more detail.

A multi-centre case-control study from five Indian cancer centres (2,320 cases of buccal mucosa cancer and 2,302 controls) found that chewing with areca nut was associated with almost double the risk of chewing without it (odds ratio 1.86). It also found that the benefit of stopping was substantial: those who had quit smoking 10 or more years earlier had 0.39 times the odds of buccal mucosa cancer compared with those who continued to smoke, and those who had quit chewing 10 or more years earlier had 0.58 times the odds compared with those who continued to chew [PMID 41657059].

In our reading, a person who uses tobacco or areca nut in any form has two reasons to act on a non-healing ulcer: their baseline risk is higher, and stopping the habit reduces risk over time. Our guide to quitting areca nut offers practical steps.

6. Delay in presentation in India

Patient interval. In a study of 261 patients with oral cancer at a tertiary cancer centre in Kerala, 54% reported a patient interval of more than 90 days, with a median of 92 days. Current smokers, patients with late-stage cancer, and those who travelled more than 30 minutes to a health facility were more likely to have an interval over 90 days [PMID 34710990].

Diagnostic interval. In a second analysis of 261 patients from Northern Kerala, the median diagnostic interval was 36 days, and 57.9% of participants had a diagnostic interval of more than 30 days. The authors recommended referral guidelines and in-service training of primary care practitioners [PMID 39421173].

Stage at diagnosis. In one North Indian tertiary centre study of 150 patients, 55% had nodal metastasis and 70% had advanced-stage cancers. Advanced-stage and node-positive patients were significantly more common among those with physician delay [PMID 40377616]. These are single-centre figures, not national rates.

Awareness. In a study of 200 patients at the Kidwai Memorial Institute of Oncology, Bengaluru, 83.5% of patients did not know that oral cancer can be diagnosed early by regular screening of the oral cavity, and 84% were not aware of the risk of getting oral cancer [PMID 37732523].

Does delay change the outcome? A meta-analysis of oropharyngeal cancer found that patients with delayed diagnosis were significantly more likely to present with an advanced-stage tumour; the pooled relative risk was 1.47 when the analysis was restricted to oral cancer, and 1.69 when delay was longer than 1 month [PMID 19758250]. A later systematic review found that a significant correlation between patient delay and advanced stage was reported in Asian studies only, whereas professional delay and total diagnostic delay were generally not correlated with advanced stage [PMID 34043480].

In our reading, the Indian evidence suggests that much of the delay occurs before patients first seek care, and seeing a dentist when an ulcer fails to heal is a practical way to shorten it.

7. The screening evidence

The only randomised trial of oral cancer screening identified by a Cochrane review was conducted in India [PMID 24254989]. In the Trivandrum cluster-randomised trial in Kerala, trained health workers performed oral visual inspection on healthy participants aged 35 years and older, with 96,517 eligible participants in the intervention group and 95,356 in the control group. In male tobacco or alcohol users, the oral cancer mortality rate ratio was 0.57; the result in female users (0.78) was not statistically significant [PMID 15936419].

At 15-year follow-up, the 12% reduction in oral cancer mortality in all individuals did not reach statistical significance. Among users of tobacco and/or alcohol in the intervention arm, there was a 24% reduction in oral cancer mortality after four rounds of screening, and among tobacco and/or alcohol users who attended all four screening rounds there was a 38% reduction in oral cancer incidence and an 81% reduction in oral cancer mortality [PMID 23265945]. The 81% figure applies only to that adherent high-risk subgroup.

The Cochrane review concluded that there is evidence that a visual examination as part of a population-based screening programme reduces the mortality rate of oral cancer in high-risk individuals, but noted that the evidence is limited to one study at high risk of bias. It found no evidence to support adjunctive technologies such as toluidine blue, brush biopsy or fluorescence imaging as screening tools to reduce mortality [PMID 24254989]. A separate Cochrane review of test accuracy concluded that there is a lack of high-certainty evidence to support screening programmes in the general population, and that frontline screeners, including general dentists, should remain vigilant for signs of OPMD and oral cancer [PMID 34891214].

In our reading, the screening evidence is strongest for people who use tobacco, areca nut or alcohol, and for those who return for repeated examinations.

8. What happens at the dental check

The examination begins with a history (duration, triggers, recurrence, pain, growth and general health) and an examination of the mouth [PMID 30701449]. If a sharp tooth, filling or denture is responsible, the dentist can correct it and arrange a review; a reassessment at about 3 weeks is used in practice to separate lesions that resolve from those needing referral [PMID 24460662].

If the lesion looks suspicious, the American Dental Association guideline states that immediate biopsy or referral to a specialist remains the single most important step, and that no available adjunct test demonstrated sufficient diagnostic accuracy to support routine use as a triage tool [PMID 28958308]. A biopsy involves removing a small piece of tissue for examination under the microscope, and the review cited above stresses its essential role in establishing a diagnosis when a lesion is not clinically identifiable [PMID 30701449].

A practical checklist for patients

The following checklist is our interpretation of the evidence above. It does not replace advice from your dentist.

How D4dent can help

D4dent's patient services let you find a dentist and book appointments online, with email or SMS reminders for appointments booked through the platform. You can also browse dental clinics by city on our clinics page. A teleconsultation can help you describe the ulcer and your history to a dentist and decide how soon an in-person examination is needed; it does not replace a physical examination or biopsy when one is required. Our symptom checker is another starting point.

Frequently asked questions

How long does a normal mouth ulcer take to heal?

The most common type, minor recurrent aphthous ulcers, are described in a review as small, painful ulcers that heal in 10 to 14 days without scarring. Ulcers caused by trauma, such as a sharp tooth or a denture, usually heal within two weeks once the cause is removed. Major aphthous ulcers are an exception: they are larger than 5 mm and can last 6 weeks or longer.

When should I see a dentist about a mouth ulcer?

In our reading, an ulcer that has not healed within two weeks, or that has not healed within two weeks of removing an obvious cause such as a sharp tooth, should be examined by a dentist. Expert reviews state that if an ulcer, lump, or red or white patch does not heal within 3 weeks, a malignancy or other serious disorder must be excluded and a biopsy may be indicated.

Can a mouth ulcer be a sign of oral cancer?

Common ulcers, such as aphthous and traumatic ulcers, usually heal within about two weeks. However, a review of ulcerated oral lesions notes that cancers in the mouth are notorious for mimicking benign ulcers, which is why a biopsy is essential when an ulcer is not clinically identifiable or does not respond to treatment as expected.

What are white and red patches in the mouth?

Leukoplakia (a white patch) and erythroplakia (a red patch) are among the oral potentially malignant disorders, which carry an increased risk of oral cancer. A meta-analysis reported malignant transformation rates of 9.5% for leukoplakia and 33.1% for erythroplakia across the included studies, so any persistent white or red patch should be examined by a dentist.

I chew tobacco or areca nut. Am I at higher risk?

Yes. An international analysis estimated that one in three oral cancers worldwide are attributable to smokeless tobacco or areca nut, and an Indian study found that chewing tobacco with areca nut was associated with almost double the risk of chewing without it. The same Indian study found that those who had stopped chewing for 10 years or more had substantially lower odds of buccal mucosa cancer than those who continued.

What happens at a dental check for a non-healing ulcer?

The dentist takes a history and examines the mouth. A clinical practice guideline from the American Dental Association states that, for patients with suspicious lesions, immediate biopsy or referral to a specialist remains the single most important recommendation, and that no available adjunct test was accurate enough to replace this step.

Limitations to keep in mind

The 3-week threshold comes from expert reviews and practice-based studies, not from a trial comparing waiting periods, and the American Dental Association guideline does not itself define a waiting period [PMID 18795514][PMID 24460662][PMID 28958308]. Malignant transformation rates vary by lesion type, and most of the oral submucous fibrosis studies were at high risk of bias [PMID 31803979][PMID 33205543]. The Indian delay and awareness studies were hospital-based and may not represent the general population [PMID 34710990][PMID 39421173][PMID 40377616][PMID 37732523]. The screening evidence rests on a single trial at high risk of bias [PMID 24254989]. Regional estimates for South and South-East Asia and south-central Asia should not be read as figures for India alone [PMID 40364456][PMID 39393386]. Figures are taken from published abstracts; readers should consult the full texts before citing specific values.

Conclusion

Common aphthous, traumatic and infective ulcers usually heal within about two weeks [PMID 8665304][PMID 41431448][PMID 11577924]. An ulcer that persists beyond this point has outlasted their usual course, and expert reviews advise that a lesion not healing within 3 weeks must be investigated to exclude malignancy [PMID 18795514]. Oral potentially malignant disorders are common in India and carry a variable risk of transformation [PMID 36159096][PMID 31803979]. In one Kerala study, more than half of patients waited over 90 days before seeking care [PMID 34710990], and visual screening has reduced oral cancer mortality in high-risk users of tobacco and alcohol in Kerala [PMID 15936419][PMID 23265945]. In our reading, the most useful step for anyone with a non-healing ulcer, particularly a tobacco or areca nut user, is to have it examined by a dentist without delay.

More in this series

Find a dentist, book online and get appointment reminders in one place. Create your D4dent patient account.

References

  1. Lau CB, Smith GP. Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options. Dermatol Ther. 2022 Jun;35(6):e15500. PMID: 35395126
  2. Ship JA. Recurrent aphthous stomatitis. An update. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Feb;81(2):141-7. PMID: 8665304
  3. Scully C, Bagan JV, Hopper C, Epstein JB. Oral cancer: current and future diagnostic techniques. Am J Dent. 2008 Aug;21(4):199-209. PMID: 18795514
  4. Warnakulasuriya S, Filho AM. Oral Cancer in the South and South-East Asia Region, 2022: Incidence and Mortality. Oral Dis. 2025 May;31(5):1398-1405. PMID: 40364456
  5. Fitzpatrick SG, Cohen DM, Clark AN. Ulcerated Lesions of the Oral Mucosa: Clinical and Histologic Review. Head Neck Pathol. 2019 Mar;13(1):91-102. PMID: 30701449
  6. Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent Clin North Am. 2014 Apr;58(2):281-97. PMID: 24655523
  7. Ashrafi F, Velte L, Schriber M, Baumhoer D, Bornstein MM. Oral squamous cell carcinoma misinterpreted as reaction to chronic mechanical trauma: report of two cases and critical review of the literature. Swiss Dent J. 2025 Dec 18;135(4):27-36. PMID: 41431448
  8. Amir J. Clinical aspects and antiviral therapy in primary herpetic gingivostomatitis. Paediatr Drugs. 2001;3(8):593-7. PMID: 11577924
  9. Coppola N, Cantile T, Adamo D, Canfora F, Baldares S, Riccitiello F, et al. Supportive care and antiviral treatments in primary herpetic gingivostomatitis: a systematic review. Clin Oral Investig. 2023 Nov;27(11):6333-6344. PMID: 37733027
  10. Sharma S, Bajpai J, Pathak PK, Pradhan A, Singh P, Kant S. Oral tuberculosis - Current concepts. J Family Med Prim Care. 2019 Apr;8(4):1308-1312. PMID: 31143712
  11. Scully C, Newman L, Bagan JV. The role of the dental team in preventing and diagnosing cancer: 3. oral cancer diagnosis and screening. Dent Update. 2005 Jul-Aug;32(6):326-8, 331-2, 335-7. PMID: 16117353
  12. Laronde DM, Williams PM, Hislop TG, Poh C, Ng S, Zhang L, et al. Decision making on detection and triage of oral mucosa lesions in community dental practices: screening decisions and referral. Community Dent Oral Epidemiol. 2014 Aug;42(4):375-84. PMID: 24460662
  13. Lingen MW, Abt E, Agrawal N, Chaturvedi AK, Cohen E, D'Souza G, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc. 2017 Oct;148(10):712-727.e10. PMID: 28958308
  14. Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Thomas G, Anju G, et al. Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India. Oral Oncol. 2013 Apr;49(4):314-21. PMID: 23265945
  15. Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, Bagan JV, González-Moles MÁ, Kerr AR, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer. Oral Dis. 2021 Nov;27(8):1862-1880. PMID: 33128420
  16. Kumbhalwar A, Shetiya SH, Kakodkar P, Mehta V, Mathur A, Porwal P. Prevalence of precancerous lesions and conditions in India: A systematic review and meta-analysis. World J Methodol. 2022 Jul 20;12(4):293-304. PMID: 36159096
  17. Iocca O, Sollecito TP, Alawi F, Weinstein GS, Newman JG, De Virgilio A, et al. Potentially malignant disorders of the oral cavity and oral dysplasia: A systematic review and meta-analysis of malignant transformation rate by subtype. Head Neck. 2020 Mar;42(3):539-555. PMID: 31803979
  18. Pimenta-Barros LA, Ramos-García P, González-Moles MÁ, Aguirre-Urizar JM, Warnakulasuriya S. Malignant transformation of oral leukoplakia: Systematic review and comprehensive meta-analysis. Oral Dis. 2025 Jan;31(1):69-80. PMID: 39314164
  19. Kujan O, Mello FW, Warnakulasuriya S. Malignant transformation of oral submucous fibrosis: A systematic review and meta-analysis. Oral Dis. 2021 Nov;27(8):1936-1946. PMID: 33205543
  20. Rumgay H, Nethan ST, Shah R, Vignat J, Ayo-Yusuf O, Chaturvedi P, et al. Global burden of oral cancer in 2022 attributable to smokeless tobacco and areca nut consumption: a population attributable fraction analysis. Lancet Oncol. 2024 Nov;25(11):1413-1423. PMID: 39393386
  21. Pullat GB, Bohrmann B, George GS, Dikshit S, Singh A, Chaturvedi P, et al. The impact of tobacco cessation on buccal mucosa cancer risk: A multi-centre case-control study in India. Int J Cancer. 2026 Jul 15;159(2):368-377. PMID: 41657059
  22. Philip PM, Kannan S. Patient Interval and Associated Factors in the Diagnostic Journey of Oral Cancer: A Hospital-Based Cross-Sectional Study from Kerala, India. Asian Pac J Cancer Prev. 2021 Oct 1;22(10):3143-3149. PMID: 34710990
  23. Philip PM, Kannan S. An inquiry into patient versus health system factors contribution to the diagnostic interval in oral cancer: an early diagnosis study from Kerala, India. Ecancermedicalscience. 2024;18:1745. PMID: 39421173
  24. Sahu GC, Shankar R, Singhavi HR, Daga D, Rai DK, Gupta M, et al. Delay in the diagnosis of oral cancer in India, time to focus toward capacity building of physicians: A prospective observational study. Indian J Cancer. 2025 Jan 1;62(1):128-134. PMID: 40377616
  25. R VC, C R, Sridhar P, Ramachandra C, Kumar M. Barriers related to Oral Cancer Screening, Diagnosis and Treatment in Karnataka, India. Gulf J Oncolog. 2023 Sep;1(43):19-24. PMID: 37732523
  26. Gómez I, Seoane J, Varela-Centelles P, Diz P, Takkouche B. Is diagnostic delay related to advanced-stage oral cancer? A meta-analysis. Eur J Oral Sci. 2009 Oct;117(5):541-6. PMID: 19758250
  27. Lauritzen BB, Jensen JS, Grønhøj C, Wessel I, von Buchwald C. Impact of delay in diagnosis and treatment-initiation on disease stage and survival in oral cavity cancer: a systematic review. Acta Oncol. 2021 Sep;60(9):1083-1090. PMID: 34043480
  28. Brocklehurst P, Kujan O, O'Malley LA, Ogden G, Shepherd S, Glenny AM. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database Syst Rev. 2013 Nov 19;2013(11):CD004150. PMID: 24254989
  29. Sankaranarayanan R, Ramadas K, Thomas G, Muwonge R, Thara S, Mathew B, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet. 2005 Jun 4-10;365(9475):1927-33. PMID: 15936419
  30. Walsh T, Warnakulasuriya S, Lingen MW, Kerr AR, Ogden GR, Glenny AM, et al. Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database Syst Rev. 2021 Dec 10;12(12):CD010173. PMID: 34891214